In the animal (in vivo) studies using topical Ig, all of the animals tested tolerated the Ig extremely well, without displaying any irritation even at high dosages. More importantly, Ig neutralized adenovirus at least as well as cidofovir, another antiviral drug that proved to be a potent inhibitor of adenovirus eye infections in early trials but was never approved by the FDA due to unacceptable side effects. According to the investigators, Ig was remarkably effective, during the early phase of infection (days 1-5) as demonstrated by the significant reduction in daily levels of virus in eye fluids compared to eye fluids obtained from control animals administered only saline.
Although this is the first study to ever demonstrate Igs ability to block adenoviral-mediated eye infections, Dr. Gambotto is only slightly surprised by the results. We use this compound in our laboratory on a regular basis to block the activity of the adenoviruses that we use in gene therapy experiments. So, we were pretty sure it would have some antiviral effects. We were not prepared, however, for it to be effective against so many strains and to demonstrate almost no toxicity, he explained.
Because conjunctivitis is so contagious, Dr. Gambotto and his investigators believe that topical Ig may be of value in many settings, including ophthalmology units in hospitals, pediatric units, community clinics and in global public health programs. Furthermore, due to its broad spectrum of antimicrobial properties, they believe that topical ocular application of Ig may be effective against other viral and bacterial causes of conjunctivitis.
'/>"/>
| Contact: Jim Swyers SwyersJP@upmc.edu 412-647-3555 University of Pittsburgh Schools of the Health Sciences Source:Eurekalert |